A trial looking at different doses of aspirin to prevent cancer in people who have Lynch syndrome (CaPP3)

Please note

This trial is no longer recruiting patients. We hope to add results when they are available.

Overview

All cancer types

Closed

Phase 3

This trial is comparing 3 different doses of aspirin as a way of stopping cancer developing in people who have Lynch syndrome.

Cancer Research UK supports this trial.

Recruitment start: 1 October 2014

Recruitment end: 31 March 2019

Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.

Professor Sir John Burn

Bayer Pharma AG

Cancer Research UK

NIHR Clinical Research Network: Genetics

Newcastle University

Newcastle upon Tyne Hospitals NHS Foundation Trust

This is Cancer Research UK trial number CRUK/12/039.

There is more information on the CaPP3 website(link is external).

Last reviewed: 25 May 2022

CRUK internal database number: 10517

About Cancer generously supported by Dangoor Education since 2010. Learn more about Dangoor Education

What to ask your doctor about clinical trials.

Meet and chat to other cancer people affected by cancer.

Questions about cancer? Call freephone 0808 800 40 40 from 9 to 5 - Monday to Friday. Alternatively, you can email us.